Anti-TNF treatment of baboons with sepsis reduces TNF-α, IL-16 and IL- 8, but not the degree of complement activation

Scandinavian Journal of Immunology

Volumn 48, Issue 5, 1998, Pages 509-514

  Bengtsson, A ^a   Redl, H ^b   Schlag, G ^b   Hogasen K ^c   Gotze O ^d   Mollnes, T E ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BABOON; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ESCHERICHIA COLI; HYPOTENSION; INFLAMMATORY INFILTRATE; LEUKOCYTE ACTIVATION; LEUKOCYTE AGGREGATION; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKIN-8; PAPIO; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031761019     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00433.x     Document Type: Article

References (28)

1. Schlag G, Redl H, Davies J, Bodmer M, Foulkes R. Humanized TNF-antibodies in a subchronic septic model in baboons with single bacterial challenge to improve survival and to prevent multi-organ failure (MOF). Circ Shock 1992;37:52-3.
2. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990;30:279-92.
3. Bahrami S, Redl H, Leichtfried G, Kober C, Wilfing C. Beneficial effects of anti-TNF monoclonal antibody (mAb) in endotoxin-induced coagulation disorders in rats. Circ Shock 1991;34: 167-71.
4. Porter SB. Current status of clinical trials with anti-TNF. Chest 1997;112:339-46.
5. Tracey KJ, Lowry SF, Fahey TJ et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone response in the dog. Surg Gynecol Obstet 1987;164:415-22.
6. Natanson C, Eichenholz PW, Danner RL et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human shock. J Exp Med 1989;169:823-32.
7. Redl H, Schlag G, Bahrami S, Schade U, Ceska M, Stütz P. Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model. J Infect Dis 1991;164: 383-8.
8. Waage A, Brandtzæg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1 and fatal outcome. J Exp Med 1989;169:333-8.
9. Baggiolini M. Neutrophils, interleukin 8, and related chemotactic cytokines. In: Sies H, Flohe L, Zimmer G, eds. Molecular Aspects of Inflammation. Heidelberg: Springer-Verlag, 1985:25.
10. Cavaillon JM, Fitting C, Haeffner-Cavallon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990;20:253-7.
11. Fromm RE, Suffredini AF, Kovacs JA, Schlesinger T, Parrillo JE. Circulating tumor necrosis factor in normal volunteers receiving endotoxin. Crit Care Med 1988;16:397-401.
12. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989;264: 1-14.
13. Scholz W, McClurg MR, Cardenas GJ, Smith M, Noonan DJ, Hugli TE. C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol immunopathol 1990;57:297-307.
14. Smedegard G, Cui L, Hugli TE. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989;135:489-97.
15. Stevens JH, O'Hanley P, Shapiro JM et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986;77:1812-16.
16. Dalmasso AP. Complement in the pathophysiology and diagnosis of human disease. Crc Crit Rev Clin Lab Sci 1986;24:123-83.
17. Hsueh W, Sun X, Rioja LN, Gonzalez Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 1990;70:309-14.
18. Rabinovici R, Yeh CG, Hillegass LM, Grisvold DE, DiMartino MJ. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 1992;149:1744-50.
19. Mollnes TE, Redl H, Högaäsen K et al. Complement activation in septic baboons detected by neoepitope specific assays for C3b/iC3b/ C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993;91:295-300.
20. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989;17:489-94.
21. Fein AM, Lippman M, Holtzman H, Eliraz A, Goldberg SK. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 1983;83:40-2.
22. Robbins R, Maunder R, Gossman G, Kendall T, Hudson L, Rennard SO. Functional loss of chemotactic factor inactivator in the adult respiratory distress syndrome. Am Rev Respir Dis 1990;141: 1463-8.
23. Hack CE, Nuijens JH, Felt-Bersma RJ et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989;86:20-6.
24. Brandtzaeg P, Mollnes TE, Kieruf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989;160:58-65.
25. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 1984;130:791-6.
26. Slotman GJ, Burchard KW, Williams JJ, D'Arrezzo A, Yellin SA. Interaction of prostaglandins, activated complement and granulocytes in clinical sepsis and hypotension. Surgery 1986;99:744-50.
27. Kellermann W, Frentzel-Beyme R, Welte M, Jochum M. Phospholipase A in acute lung injury after trauma and sepsis: its relation to the inflammatory mediators PMN-elastase, C3a, and Neopterin. Klin Wochenschr 1989;67:190-5.
28. Hangen DH, Bloom RJ, Stevens JH et al. Adult respiratory distress syndrome. A live E. coli septic primate model. Am J Pathol 1987; 126:396-400.